We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,523

Federal Court of Appeal provides much-needed clarity on the “obvious to try” test and meaning of “inventive concept”
  • Osler Hoskin & Harcourt LLP
  • Canada
  • April 18 2017

The Federal Court of Appeal (the Court) has now provided much-needed clarity and guidance on two critical points in Canadian patent law


April 2017 International Trade Compliance Update
  • Baker McKenzie
  • Canada, European Union, United Kingdom, USA
  • April 12 2017

The WTO announced that WTO members discussed five new or enhanced proposals to advance services negotiations at meetings of the Working Party on


Range in dosage regimen claims found not to invoke physician’s judgement
  • Bereskin & Parr LLP
  • Canada
  • April 17 2017

There has been a significant amount of uncertainty in Canada regarding the patentability of use claims which include dosages and dosage regimens


Court of Appeal Dismisses Appeal for Different Reasons and Provides Review of the Obvious to Try Test
  • Borden Ladner Gervais LLP
  • Canada
  • April 19 2017

The Court of Appeal dismissed Bristol-Myers Squibb's appeal from the Trial Judge's decision refusing its application for a writ of prohibition on the


CIALIS Patent Survives Validity Challenge on Appeal
  • McCarthy Tétrault LLP
  • Canada
  • May 19 2016

Last year we wrote about a trilogy of Federal Court decisions relating to Eli Lilly’s erectile dysfunction (ED) drug CIALIS (tadalafil). While Lilly


Court of Appeal Grants Appeal as it Relates to Duty to Mitigate
  • Borden Ladner Gervais LLP
  • Canada
  • April 19 2017

In this decision, the Court of Appeal was considering an appeal by Apotex of various findings of the Court relating to its action seeking damages from


Apotex Granted Leave to Expand Scope of Evidence Available to Prove its NIA Plea
  • Borden Ladner Gervais LLP
  • Canada
  • April 12 2017

In this recently reported decision, the Court granted Apotex leave to deliver Fresh as Amended Responding Statement of Issues for the reference into


Competitionantitrust law
  • Dentons
  • Germany, OECD, United Kingdom, USA, Australia, Canada, China, European Union
  • February 9 2017

In the wake of the 2016 elections, we now await the decision as to who will be the "antitrust guard" at the top of the US Department


Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK


Government of Canada Successful in Eli Lilly NAFTA Patent Arbitration
  • Aird & Berlis LLP | Aird & McBurney LP
  • Canada
  • March 20 2017

The NAFTA Arbitration Tribunal in the Eli Lilly "Promise of the Patent" doctrine proceeding has issued a ruling, and it appears that the result is